Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 Suppl. 2: S14–21. ArticlePubMed Google Scholar
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–53. ArticlePubMed Google Scholar
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34. ArticlePubMedCAS Google Scholar
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53. Article Google Scholar
Betteridge DJ. Treating dyslipidaemia in the patient with type 2 diabetes. Eur Heart J Suppl 2004; 6 Suppl. C: C28–33. ArticleCAS Google Scholar
Drexel H, Aczel S, Marte T, et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005; 28: 101–7. ArticlePubMedCAS Google Scholar
Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733–49. ArticlePubMed Google Scholar
Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Blood Press 1998; 7: 262–9. ArticlePubMedCAS Google Scholar
NCEP Adult Treatment Panel III. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults final report. Circulation 2002; 106: 3143–421. Google Scholar
World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization, 1999. Google Scholar
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9. ArticlePubMed Google Scholar
Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004; 27: 2444–9. ArticlePubMed Google Scholar
Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 2001; 249: 225–35. ArticlePubMedCAS Google Scholar
McKenney JM. Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal. Pharmacotherapy 2003; 23: 26S–33S. ArticlePubMed Google Scholar
Eschwege E. The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications. Diabetes Metab 2003; 29: 6S19–27. ArticlePubMedCAS Google Scholar
Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–16. ArticlePubMed Google Scholar
Cziraky MJ. Management of dyslipidemia in patients with metabolic syndrome. J Am Pharm Assoc (Wash) 2004; 44: 478–88. Google Scholar
Steiner G. Fibrates in the metabolic syndrome and in diabetes. Endocrinol Metab Clin North Am 2004; 33: 545–55, vi-vii. ArticlePubMedCAS Google Scholar
Lehto S, Ronnemaa T, Haffner SM, et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 46: 1354–9. ArticlePubMedCAS Google Scholar
Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–8. ArticlePubMedCAS Google Scholar
Papadakis JA, Milionis HJ, Press M, et al. Treating dyslipidaemia in non-insulindependent diabetes mellitus: a special reference to statins. J Diabetes Complications 2001; 15: 211–26. ArticlePubMedCAS Google Scholar
Kendall DM. The dyslipidemia of diabetes mellitus: giving triglycerides and highdensity lipoprotein cholesterol a higher priority? Endocrinol Metab Clin North Am 2005; 34: 27–48. ArticlePubMedCAS Google Scholar
Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453–62. ArticlePubMedCAS Google Scholar
BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention study. Circulation 2000; 102: 21–7. Article Google Scholar
Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27 Suppl. 1: S68–71. ArticlePubMed Google Scholar
De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–10. ArticlePubMed Google Scholar
Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16. ArticlePubMed Google Scholar
Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58. ArticlePubMedCAS Google Scholar
ALLHAT-LLT Trial Investigators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2002; 288: 2998–3007. Article Google Scholar
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96. ArticlePubMedCAS Google Scholar
Garg A. Statins for all patients with type 2 diabetes: not so soon. Lancet 2004; 364: 641–2. ArticlePubMed Google Scholar
Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165: 1154–60. ArticlePubMedCAS Google Scholar
Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001; 3: 83–92. ArticlePubMedCAS Google Scholar
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–8. ArticlePubMedCAS Google Scholar
Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs Highdensity lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002; 162: 2597–604. ArticlePubMedCAS Google Scholar
Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21: 641–8. ArticlePubMedCAS Google Scholar
Diabetes Atherosclerosis Intervention Study. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905–10. Article Google Scholar
Keech A. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 2005 Aug 22; 4(1): 13. ArticlePubMed Google Scholar
FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [ISRCTN64783481]. Cardiovasc Diabetol 2004; 3: 9.
Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120–2. ArticlePubMedCAS Google Scholar
Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002; 90: 50K–60K. ArticlePubMedCAS Google Scholar
Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1280–7. ArticlePubMedCAS Google Scholar
Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin-treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85: 544–8. ArticlePubMedCAS Google Scholar
Reliant Pharmaceuticals Inc. Omacor® (omega-3-acid ethyl esters) prescribing information. Liberty Corner (NJ): Reliant Pharmaceuticals Inc., 2005 Apr. Google Scholar
Betteridge DJ, Morrell JM. Clinician’s guide to lipids and coronary heart disease. 2nd ed. London: Arnold, 2003. Google Scholar
The Lipid Research Clinics Coronary Primary Prevention Group. The lipid research clinics coronary primary prevention trial results: I. reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64. Article Google Scholar
Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once a night versus plain niacin in the management of hyperlipidemia. Metabolism 1998; 47: 1097–104. ArticlePubMedCAS Google Scholar
Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1092–7. ArticlePubMedCAS Google Scholar
Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729–41. ArticlePubMedCAS Google Scholar
Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 629 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409–15. ArticlePubMedCAS Google Scholar
Betteridge DJ, Clark RAC, Choudhury RP. Lipid disorders: ezetimibe. Drugs in Context — General Medicine 2004; 1(2): 37–72. Google Scholar